Search results
Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?
Motley Fool via Yahoo Finance· 4 days agoAnalysts predict that tirzepatide's peak sales could reach $25 billion, but to get there, Eli Lilly...
Increasing number of employers covering GLP-1 drugs for weight loss, survey finds
BenefitsPRO· 5 days agoInsurer resistance to covering the drugs is a limiting factor for sales growth for drugmakers,...
Scams tied to Ozempic and other new weight-loss drugs are surging. How to protect yourself
San Jose Mercury News· 5 days agoOzempic, Wegovy and other new weight-loss drugs have proved so good at helping users shed pounds,...
A Surprise Big Name Enters The Weight-Loss Melee
Investor's Business Daily· 5 days agoInstead, the company posted the results from testing in monkeys in...indeed, Gilead has an oral GLP-1 approaching Phase 1." Over the course of 36 days,...
Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster | The Motley Fool
The Motley Fool· 5 days agoEli Lilly's (LLY -0.55%) name has become somewhat synonymous with its work in diabetes and obesity...
Gateway - Quartz
Quartz· 2 days agoCustomers will be able to get a prescription for the drug from a licensed health care provider directly on the platform. The announcement...GLP-1 medications, the class of ...
Nvidia and these other megacap stocks are extremely overbought and could be due for a near-term...
CNBC· 12 hours agoNow that megacap stocks have lifted the S & P 500 and Nasdaq Composite indexes to all-time highs,...
Broadcom Is on Track to Edge Past Eli Lilly’s Market Value. AI Is Helping It Do So.
Barrons.com· 2 days ago“Broadcom’s second quarter results were once again driven by AI demand and VMware,” Broadcom CEO...
Taking a GLP-1 medicine? Here's what experts say you should eat
Medical Xpress· 4 days agoFolks using a weight-loss drugs like Ozempic, Wegovy or Zepbound still have nutritional requirements...
Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?
The Motley Fool via AOL· 4 days agoAnalysts predict that tirzepatide's peak sales could reach $25 billion, but to get there, Eli Lilly will have to earn more indications for its new crown ...
